<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075060</url>
  </required_header>
  <id_info>
    <org_study_id>IPOI vs IPOP</org_study_id>
    <nct_id>NCT02075060</nct_id>
  </id_info>
  <brief_title>Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer</brief_title>
  <acronym>IPOI vs IPOP</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to assess the efficacy and toxicity of immediate pre-operative
      instillation of mitomycin C compared to the standard early post-operative .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Non Muscle-invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>IPOI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPOI (pre-operative)</intervention_name>
    <arm_group_label>IPOI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPOP (post-operative)</intervention_name>
    <arm_group_label>IPOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years,

          -  Primary or recurrent bladder tumor with endoscopic papillary aspect,

          -  One or two bladder tumors,

          -  Cytology before TURB showing no high-grade cells,

          -  Patients without tutorship or subordination (ou curatorship),

          -  Patients under the general social security system or qualifying through a third party,

          -  Informed consent signed by the patient after clear and fair information.

        Exclusion Criteria:

          -  Age &lt; 18 years,

          -  Allergy to mitomycin C,

          -  Traumatic stenting,

          -  Upper tract urothelial cancer,

          -  Urethral invasion,

          -  History of muscle invasive bladder cancer,

          -  Extensive tumor (3 cm or more),

          -  Any contraindication to TURB,

          -  Simultaneous participation in another clinical research study,

          -  Patients not insured by the social security or not qualifying through a third party,

          -  Patients with enhanced protection, namely pregnant or lactating women, persons
             deprived of their liberty by a judicial or administrative decision, people staying in
             a health or social institution, adults under legal protection, and finally patients in
             emergency situations,

          -  Pregnant or lactating females or women of childbearing potential not willing to use an
             adequate method of birth control for the duration of the study (i.e. hormonal /
             mechanical contraceptive : oral, injectable, transdermal, implantable, intrauterine or
             surgical device: tubal ligation, hysterectomy, total oophorectomy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques IRANI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques IRANI, MD, PhD</last_name>
    <phone>: +33 (0)5.49.44.44.77</phone>
    <email>jacques.irani@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bicêtre Hospital</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldine PIGNOT, MD</last_name>
      <phone>+33-1 45 21 36 98</phone>
      <email>gg_pignot@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques IRANI, MD, PhD</last_name>
      <phone>+33 (0)5.49.44.44.77</phone>
      <email>jacques.irani@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques IRANI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low-grade</keyword>
  <keyword>NMIBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

